The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the ...

Shares in Denmark's global healthcare company, Novo Nordisk jumped sharply on Friday after the U.K.'s regulator signed off on ...

The U.K.’s health regulator approved a higher dose of Novo Nordisk’s Wegovy weight-loss drug applicable to patients with a ...

We recently published 10 Stocks Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer ...

Novo Nordisk shares climbed about 4% on Friday, touching levels last seen in October, after early U.S. prescription data for its Wegovy w ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Novo, the maker of the obesity drug Wegovy, has repeatedly warned about the risks of compounded and knock-off versions of GLP ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it ...

Strive Specialities Inc., a major provider of compounded medicines, filed a federal lawsuit against pharmaceutical giants Eli ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

Health-care companies rose after a strong launch for one potential blockbuster. The pill formulation of Danish drug maker Novo Nordisk's Wegovy weight-control medication garnered almost as many ...